LCB67

LCB67 is a **DLK1-targeting antibody-drug conjugate (ADC)** developed using LegoChem Biosciences' next-generation ADC platform. The drug combines an anti-DLK1 monoclonal antibody, licensed from Y-Biologics, with a cytotoxic payload, designed for the treatment of various solid tumors including liver cancer and small cell lung cancer. DLK1 (Delta-like 1 homolog) is a novel target implicated in several tumor types. The ADC mechanism involves targeted delivery of a cytotoxic agent (likely a tubulin inhibitor in the auristatin class) to DLK1-expressing tumor cells, inhibiting cell division and promoting cancer cell death. LCB67 is licensed worldwide for development and commercialization to Pyxis Oncology, with co-development input from Y-Biologics. As of the most recent updates, LCB67 is in preclinical or early-phase development for multiple solid tumors and selected hematologic malignancies[1][3].

Other names

DLK1-ADCDLK-1-ADCDLK 1-ADC